InBios is a leading biotechnology company based in Seattle, Washington (USA). At InBios, we believe an accurate diagnosis is the first step to effective treatment.
In response to the COVID-19 outbreak, InBios is working diligently to develop new tests. Today, we are pleased to announced that InBios has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for our Smart Detect™ SARS-CoV-2 rRT-PCR Kit.
This real-time PCR test is intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19.
Our test can be used in all hospital and lab systems.
Kit tests 45 unknown patient specimens
Sample types: human nasopharyngeal, anterior & mid-turbinate nasal swab specimens
Results in ~4 hours
Validated on Applied Biosystems 7500 Fast Dx Real-Time PCR and the Biorad CFX96 Touch Real-Time PCR Detection System instruments
